GlassScriptPhysician profile
Ernest A Little
NPI 1780779199
$52,041.89
in general payments reported to CMS, 2019-2025
15 companies · $204 in 2025
The $204 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $7,173 · 2021: $6,697 · 2022: $7,763 · 2023: $9,744 · 2024: $944 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $4,950 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,200 · Food and Beverage: $1,301 · Travel and Lodging: $1,265 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $4,950.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,200.00 |
| Food and Beverage | $1,301.32 |
| Travel and Lodging | $1,265.35 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $25,663.08 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $10,146.01 | 2022-2024 | Andexxa |
| Alexion Pharmaceuticals, INC. | $7,782.41 | 2020-2025 | Ultomiris |
| Horizon Therapeutics Plc | $6,978.45 | 2021-2023 | Uplizna |
| Amgen INC. | $317.44 | 2024-2025 | Uplizna |
| Avanir Pharmaceuticals, INC. | $273.27 | 2019 | |
| Janssen Pharmaceuticals, INC | $215.09 | 2019-2021 | |
| Silk Road Medical, INC. | $164.80 | 2019-2021 | |
| Portola Pharmaceuticals, LLC | $151.63 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $149.39 | 2021 | |
| Medtronic, INC. | $125.00 | 2024 | Linq II |
| Tg Therapeutics, INC. | $26.06 | 2024 | |
| Biogen, INC. | $23.62 | 2019 | |
| Genentech USA, INC. | $13.36 | 2019 | |
| Acadia Pharmaceuticals INC | $12.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernest Little listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.